• +1-646-491-9876
    • +91-20-67278686

    Search

    Neuronal Acetylcholine Receptor Subunit Alpha 7-Pipeline Review H2 2017

    Neuronal Acetylcholine Receptor Subunit Alpha 7-Pipeline Review H2 2017

    • Report Code ID: RW0001881483
    • Category Life Sciences
    • No. of Pages 72
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Pipeline Review H2 2017

    Summary

    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Pipeline Review H2 2017 outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.

    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II Phase I and Preclinical stages are 5 4 and 5 respectively. Similarly the universities portfolio in Preclinical stages comprises 3 molecules respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Alzheimer's Disease Cognitive Impairment Associated With Schizophrenia (CIAS) Schizophrenia Attention Deficit Hyperactivity Disorder (ADHD) Bipolar Disorder (Manic Depression) Cognitive Disorders Cognitive Impairment Parkinson's Disease Smoking Addiction Chronic Pain Complex Regional Pain Syndrome Dementia Associated With Alzheimer's Disease Generalized Anxiety Disorder (GAD) Major Depressive Disorder Neurodegenerative Diseases Neuropathic Pain Obesity Pain Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury.

    Furthermore this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
    - The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Overview
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Companies Involved in Therapeutics Development
    Bionomics Ltd
    Bristol-Myers Squibb Company
    CoMentis Inc
    Johnson & Johnson
    Merck & Co Inc
    NeuroDerm Ltd
    Saniona AB
    SK Biopharmaceuticals Co Ltd
    Vanda Pharmaceuticals Inc
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Drug Profiles
    (nicotine + opipramol hydrochloride)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AN-761-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AQW-051-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVL-3288-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVL-8168-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-910731-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNC-210-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BNC-375-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gln-1062-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GTS-21-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-39393406-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NBP-14-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKLA-4R-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer's Disease and Schizophrenia-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize CHRNA7 for Central Nervous System-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Dormant Products
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Discontinued Products
    Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)-Product Development Milestones
    Featured News & Press Releases
    Jun 15 2017 Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
    May 18 2017 Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention
    Feb 03 2017 Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment
    Jan 09 2017 Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase
    Sep 21 2016 Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder
    Sep 16 2016 Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP
    Jun 30 2016 Bionomics To Trial Drug Against Post-Traumatic Stress Disorder
    Jun 24 2016 Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial
    Mar 29 2016 Neurodyn Cognition to Present Memogain Clinical Developments at Neurotech Investing and Partnering Conference
    Dec 08 2015 Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
    Sep 16 2015 Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression
    Apr 20 2015 Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety
    Feb 02 2015 Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210
    Nov 17 2014 Bionomics to Present BNC210 at Society for Neuroscience Meeting
    Nov 11 2014 Bionomics to Progress BNC210 in Clinical Trials
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Bionomics Ltd H2 2017
    Pipeline by Bristol-Myers Squibb Company H2 2017
    Pipeline by CoMentis Inc H2 2017
    Pipeline by Johnson & Johnson H2 2017
    Pipeline by Merck & Co Inc H2 2017
    Pipeline by NeuroDerm Ltd H2 2017
    Pipeline by Saniona AB H2 2017
    Pipeline by SK Biopharmaceuticals Co Ltd H2 2017
    Pipeline by Vanda Pharmaceuticals Inc H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Dormant Products H2 2017 (Contd..2) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Bionomics Ltd
    Bristol-Myers Squibb Company
    CoMentis Inc
    Johnson & Johnson
    Merck & Co Inc
    NeuroDerm Ltd
    Saniona AB
    SK Biopharmaceuticals Co Ltd
    Vanda Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//neuronal-acetylcholine-receptor-subunit-alpha-7-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments